- ICH GCP
- US Clinical Trials Registry
- Clinical Trial NCT02111291
Santyl Applications to Diabetic Foot Ulcers
Clinical Outcomes Associated With Enzymatic Debridement of Diabetic Foot Ulcers for Up To 12 Weeks With Clostridial Collagenase (Santyl®) Ointment
Study Overview
Status
Conditions
Intervention / Treatment
Study Type
Enrollment (Actual)
Phase
- Phase 4
Contacts and Locations
Study Locations
-
-
Alberta
-
Calgary, Alberta, Canada, T2T 5C7
-
-
Ontario
-
Hamilton, Ontario, Canada, L8R2R3
-
-
Quebec
-
Montreal, Quebec, Canada, J4B 5E4
-
-
-
-
Arizona
-
Mesa, Arizona, United States, 85206
-
-
California
-
Carlsbad, California, United States, 92009
-
Castro Valley, California, United States, 94546
-
Fair Oaks, California, United States, 95628
-
Fresno, California, United States, 93720
-
Sylmar, California, United States, 91342
-
-
Florida
-
Doral, Florida, United States, 33178
-
-
Georgia
-
Warner Robins, Georgia, United States, 31093
-
-
Louisiana
-
Shreveport, Louisiana, United States, 71101
-
-
Maryland
-
Baltimore, Maryland, United States, 21215
-
-
Missouri
-
Kansas City, Missouri, United States, 64114
-
-
Nevada
-
Las Vegas, Nevada, United States, 89119
-
-
New York
-
New York, New York, United States, 10025
-
-
North Carolina
-
Greenville, North Carolina, United States, 27834
-
-
Pennsylvania
-
Reading, Pennsylvania, United States, 19610
-
York, Pennsylvania, United States, 17402
-
-
Texas
-
Fort Worth, Texas, United States, 76104
-
McAllen, Texas, United States, 78501
-
Temple, Texas, United States, 76504
-
-
Utah
-
Saint George, Utah, United States, 84770
-
-
Virginia
-
Roanoke, Virginia, United States, 24013
-
Virginia Beach, Virginia, United States, 23464
-
-
Participation Criteria
Eligibility Criteria
Ages Eligible for Study
Accepts Healthy Volunteers
Genders Eligible for Study
Description
Inclusion Criteria:
Subjects will be considered qualified for enrollment if they meet the following criteria:
- Provide written informed consent, which will consist of reading, signing, and dating the informed consent document after the Investigator, sub-Investigator or other designated study staff member has explained the study procedures, risks, and contact information.
- Eighteen (18) years of age or older, of either sex, and of any race or skin type provided that their skin color, in the opinion of the Investigator, will not interfere with the study assessments.
- Willing and able to make all required study visits.
- Able to follow instructions and perform the dressing changes at home or have a caregiver who can perform the dressing changes according to the protocol.
- Willing to use an appropriate off-loading device whenever necessary to keep weight off of any foot ulcers.
- An ulcer present on any part of the plantar surface of the foot or plantar surface of the hallux which is 0.5 cm2 - 10 cm2 inclusive (as measured at the Screening Visit) with a duration ≥ 6 weeks but not more than 52 weeks (12 months) documented in the patient's history or by patient report of onset which requires debridement.
- Adequate arterial blood flow as evidenced by an ankle brachial index (ABI) of > 0.70 and ≤ 1.20. If ABI > 1.2, perfusion at or near the site of the ulcer should be confirmed; the foot is warm to the touch and has palpable pulses.
- Separation of at least 5 cm (closest ulcer edge to other closest ulcer edge) if ≥ 2 ulcers are present.
- Diabetes mellitus (Type 1 or 2) requiring insulin or oral/injectable medications to control blood glucose levels.
- Target ulcer is not infected based on clinical assessment.
Exclusion Criteria:
Any one (1) of the following criteria will disqualify a potential Subject from participation in the study.
- Contraindications or hypersensitivity to the use of clostridial collagenase or hydrogel.
- Undergoing therapy with another investigational agent within thirty (30) days of Visit 1, or planned participation overlapping with this study.
- Bleeding disorder that would preclude sharp debridement during the study.
- Active cellulitis of the target ulcer, lymphangitic streaking, deep tissue abscess, gangrene, or infection of muscle, tendon, joint or bone.
- Infection with systemic toxicity or metabolic instability (e.g., fever, chills, tachycardia, hypotension, confusion, vomiting, leukocytosis, acidosis, severe hyperglycemia, azotemia).
- A target ulcer which involves the underlying tissues of tendon, muscle, or bone.
- Diagnosis of chronic granulomatous disease, leukocyte adhesion defects, or severe neutropenia.
Current treatment (at the time of the Screening Visit) with any of the following:
- Systemic corticosteroids. If corticosteroid treatment was for ≥ 10 days, there must be a 1 week interval between discontinuation and screening.
- Immunosuppressive agents
- Chemotherapeutic agents
- Antiviral agents
- Systemic antibiotic therapy or topical antibiotic treatment of the target ulcer
Treatment of target ulcer with bioactive therapies within 1 month of screening:
- Platelet-derived growth factor (e.g., Regranex)
- Living skin equivalent (e.g., Apligraf)
- Dermal substitute (e.g., Dermagraft, Integra, Oasis, etc.)
- Treatment of target ulcer for any length of time with clostridial collagenase ointment (SANTYL®) if within 12 weeks prior to screening.
- Target ulcer that failed to develop well-established granulation tissue when treated with clostridial collagenase ointment (SANTYL®) for at least 4 weeks.
- Radiation therapy to the target lower extremity within 30 days prior to screening.
- Medical or physical condition that, in the opinion of the Investigator, would preclude safe subject participation in the study.
Blood counts and blood chemistry values as follows:
- Alanine aminotransferase (ALT) > 3x upper limit of normal
- Aspartate aminotransferase (AST) > 3x upper limit of normal
- Gamma Glutamyl Transferase (GGT) > 2.5x upper limit of normal
- Serum albumin < 2.0 g/dL • Pre-albumin levels of < 10 mg/dL
- Alkaline phosphatase > 500 U/L • Serum total bilirubin > 3.0 mg/dL
- Serum BUN > 75 mg/dL • Serum creatinine > 4.5 mg/dL
- HbA1c > 12% • Hemoglobin (Hgb) < 8.0 g/dL
- WBC < 2.0 x 109/L • Absolute neutrophil count < 1.0 x 109/L
- Platelet count < 50 x 109/L • INR > 1.5x upper limit of normal
Furthermore, prior to randomization at Visit 1, the following exclusion criteria will apply:
- Use of excluded concomitant medications or therapies between Screening and Visit 1.
- A clinically diagnosed infection of the target ulcer requiring treatment.
- Muscle, tendon, or bone exposure in the target ulcer.
- After debridement at Visit 1, the ulcer area is >12 cm2.
Study Plan
How is the study designed?
Design Details
- Primary Purpose: Treatment
- Allocation: Randomized
- Interventional Model: Parallel Assignment
- Masking: None (Open Label)
Arms and Interventions
Participant Group / Arm |
Intervention / Treatment |
---|---|
Experimental: SANTYL®
|
Daily application directly to the ulcer bed, approximately 2 mm thick.
|
Sham Comparator: Supportive Care
|
Daily application of hydrogel directly to the ulcer bed (if necessary), covered with foam dressing
|
What is the study measuring?
Primary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Time to Well-established Granulation Tissue
Time Frame: 12 Weeks
|
12 Weeks
|
Secondary Outcome Measures
Outcome Measure |
Time Frame |
---|---|
Adverse Event
Time Frame: 12 Weeks
|
12 Weeks
|
Collaborators and Investigators
Sponsor
Investigators
- Study Chair: Hebert B Slade, MD, Smith and Nephew Biotherapeutics
Study record dates
Study Major Dates
Study Start
Primary Completion (Actual)
Study Completion (Actual)
Study Registration Dates
First Submitted
First Submitted That Met QC Criteria
First Posted (Estimate)
Study Record Updates
Last Update Posted (Estimate)
Last Update Submitted That Met QC Criteria
Last Verified
More Information
Terms related to this study
Keywords
Additional Relevant MeSH Terms
Other Study ID Numbers
- 017-101-09-034
Drug and device information, study documents
Studies a U.S. FDA-regulated drug product
Studies a U.S. FDA-regulated device product
product manufactured in and exported from the U.S.
This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.
Clinical Trials on Diabetic Foot Ulcers
-
CytomedixCTI Clinical Trial and Consulting ServicesTerminatedDiabetic Foot Ulcers | Wounds | Pressure Ulcers | Leg UlcersUnited States
-
Smith & Nephew, Inc.CompletedDiabetic Foot Ulcers | Venous Leg UlcersUnited States, Canada
-
Arteriocyte, Inc.TerminatedDiabetic Foot Ulcers | Pressure Ulcers | Venous UlcersUnited States
-
Integra LifeSciences CorporationMayo Clinic; Temple University; Samuel Merritt University; New York College of... and other collaboratorsCompletedFoot Ulcers, DiabeticUnited States
-
HealthpointCompletedDiabetic Foot Ulcers | Pressure UlcersUnited States
-
HealthpointCompletedDiabetic Foot Ulcers (DFU) | Venous Stasis Ulcers (VSU)United States
-
Oneness Biotech Co., Ltd.Completed
-
Hadassah Medical OrganizationUnknown
-
Systagenix Wound ManagementUnknownDiabetic Foot UlcersItaly, United States, United Kingdom, Germany, Spain
-
Southern California Institute for Research and...Heritage Medical Research InstituteUnknownDiabetic Foot UlcersUnited States
Clinical Trials on Collagenase SANTYL® Ointment
-
HealthpointCompletedDiabetic Foot Ulcers | Diabetic Foot WoundsUnited States
-
HealthpointCompleted
-
University of MiamiCompletedDiabetic Foot | Foot UlcerUnited States
-
Integra LifeSciences CorporationTerminated
-
University of Kansas Medical CenterUnknownBurn, Partial ThicknessUnited States
-
Louisiana State University Health Sciences Center...HealthpointTerminatedPressure Ulcer | Soft Tissue Necrosis Lower LimbUnited States
-
Smith & Nephew, Inc.Terminated
-
Endo PharmaceuticalsCompletedAdvanced Dupuytren's DiseaseAustralia
-
Endo PharmaceuticalsCompletedA Pharmacokinetic Study of AA4500 (XIAFLEX™, Proposed Name) in Subjects With Dupuytren's ContractureDupuytren's ContractureUnited States